Start free

PolicyChanges tracks payer policy changes for medical practices and tells you what to do before they take effect.

Create a free accountPolicy Monitoring is free. No card required.
← Back to list
Independence Blue CrossMedicare Advantage · Coverage · Pharmacy · Rheumatology, Gastroenterology, Dermatology +4 moreMedium impact

MA08.019p, Intravenous Infliximab and Related Biosimilars

Act
by Sep 30, 2025
Effective date
Oct 1, 2025
Identified
Jun 19, 2026

Summary

Independence Blue Cross Medicare Advantage policy MA08.019q (effective 10/01/2025) supersedes MA08.019p and adds ICD-10 diagnosis code M05.A (Abnormal rheumatoid factor and anti-citrullinated protein antibody with rheumatoid arthritis) to the covered indications for intravenous infliximab and related biosimilars. Billing teams must update diagnosis code mappings and claim validation logic to recognize this new code as a medically necessary indication for infliximab coverage.

Get alerts when payers change rules like this one

We check Independence Blue Cross and other payers every day and email you when a change matches your specialty and state.

Get Independence Blue Cross alertsPolicy Monitoring is free. No card required.

What to do

by Sep 30, 2025 · 5 steps
01Billing team must update claim processing system to recognize ICD-10 code M05.A as a covered diagnosis for infliximab products (J1745, Q5103, Q5104, Q5121) under MA08.019q.
02Update prior authorization logic and claim validation rules to accept M05.A without additional medical review when submitted with these HCPCS codes.
03Notify providers that M05.A claims for infliximab therapy will be processed under the new policy effective 10/01/2025.
04Verify billing software reflects MA08.019q (not superseded MA08.019p).
05Claims submitted with M05.A after the effective date without proper coding updates may experience delays or denials.

Codes mentioned

J1745Q5103Q5104Q5121M05.A

Original notice

MA08.019p, Intravenous Infliximab and Related Biosimilars
medpolicy.ibx.com · Always check the source before changing claims.
View original ↗

Related changes

See all Independence Blue Cross changes →
MA08.019o, Intravenous Infliximab and Related BiosimilarsMediumEffective Apr 21, 2025 · PharmacyMA08.019q, Intravenous Infliximab and Related BiosimilarsMediumEffective Jan 1, 2026 · Pharmacy08.00.34v, Intravenous Infliximab and Related BiosimilarsMediumEffective Apr 21, 2025 · Pharmacy08.00.34w, Intravenous Infliximab and Related BiosimilarsMediumEffective Oct 1, 2025 · PharmacyBrowse every Independence Blue Cross change in the policy list

Related policy hubs

Independence Blue Cross policiesRheumatologyGastroenterologyDermatologyOphthalmologyOncologyPediatricsPharmacyCode J1745Code Q5103Code Q5104Code Q5121Code M05.A

Summaries are AI-assisted. Always confirm against the original payer notice.

What is PolicyChanges

One workspace for payer rules, prior auth, coding and compliance

Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.

Policy MonitoringPayer policy, prior auth and coding changes, filtered to your saved searchesOIG ScreeningStaff and vendors screened every month against OIG LEIE, SAM.gov and state Medicaid listsPrior Auth LookupKnow if a service needs prior authorization before you schedule itCredentialing TrackerLicenses, CAQH, Medicare revalidation and payer enrollments, with reminders before anything lapsesCompliance CenterKeep your HIPAA program documented and ready to show
Start freePolicy Monitoring is free. No card required.
Get alerts for changes like thisPolicy Monitoring is free. No card required.Create a free account